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Background: There are few published reports on severe Plasmodium vivax malaria in Africa.
Methods: Clinical pattern/manifestations of severe P. vivax were described in children admitted at New Halfa
Hospital in Sudan between September 2009-December 2011.
Results: Eighteen children were admitted at the hospital during the study period with different manifestations of
severe P. vivax malaria namely: severe anaemia (6, 33.3%), jaundice (5, 27.8%), thrombocytopenia (4, 22.2%),
hypotension (3, 16.7%), cerebral malaria (2, 11.1%), epistaxis (2, 11.1%), renal impairment (1, 5.5%), hypogylcaemia
and more than one manifestation (5, 27.8%).
By day 2, all patients were asymptomatic, a parasitaemic and had started oral quinine and primaquine. There was
no death among these patients
Conclusion: Severe P. vivax malaria is an existing entity in eastern Sudan. Further studies are required to
understand emergence of severe P. vivax malaria.Background
Malaria remains one of the most important parasitic
infections in the world, with almost 225 million cases of
infection and 0.78 million deaths in 2009, mainly in Africa,
Asia and South America [1]. Plasmodium vivax is the sec-
ond most common cause of malaria in the world after
Plasmodium falciparum, moreover, P. vivax has a wider
geographical distribution, where more people are at risk of
infection (2.85 billion) [2], and it is more difficult to con-
trol because of the hypnozoite forms of the parasite [3,4].
Recent reports on P. vivax infections suggest that this
parasite may be evolving and adapting to new epidemio-
logical contexts, becoming not only more virulent but also
more frequent in countries where the incidence has trad-
itionally been low [3,5,6]. Furthermore, it has been shown
that P. vivax is able to infect even Duffy-negative African
patients [7].
This previous old paradigm of P. vivax as “benign ter-
tian malaria” has been challenged recently by recent* Correspondence: ishagadam@hotmail.com
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reproduction in any medium, provided the orreports and documentation of severe P. vivax disease,
and even deaths due to P vivax mono-infections [8-12].
Interestingly, in one of these studies, P. vivax malaria
was confirmed by polymerase chain reaction (PCR) [12].
The vast majority of these reports on severe P. vivax
malaria are from south East Asia and India, there are
few published data on severe P. vivax from Africa [13].
The current study was conducted at New Halfa hospital
in the eastern Sudan during the period of September
2009-December 2011 to investigate manifestations of se-
vere P. vivax among children so as to add to the previ-
ous studies on severe malaria and its treatment in Sudan
[14-17]. Such data is of paramount importance for the
care givers, health planners and for controlling the dis-
ease e.g. by using an effective drug and eradicating this
species. P. falciparum (95%) was the main species in the
area and P. vivax was rare and constituted only 3% of
the species in the area [18].
Methods
Children with symptoms and signs of malaria including:
fever, chills, malaise, headache, vomiting or other systemic
complaints were included in this study after informedral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 The admission variables of the Sudanese children
with severe P. vivax malaria (n=18) at New Halfa
Hospital, Eastern Sudan
Variable Mean (standard deviation)
Age, years 4.9 (2.4)





White blood cells 5.6(2.1)
Parasitaemia, geometric mean parasite/μ/l 14280




Mahgoub et al. Parasites & Vectors 2012, 5:154 Page 2 of 4
http://www.parasitesandvectors.com/content/5/1/154consent was obtained from the parents/adolescent them-
selves. Then the details of the medical history were
gathered for each patient (age, sex, axillary temperature,
weight, fever history) using questionnaires. Children with
one or more of the manifestations of severe malaria
according to the World Health Organization [19] criteria,
which include cerebral malaria (unarousable coma), convul-
sion (more than two per 24 hours), hypotension (systolic
blood pressure< 80 mmHg with cold extremities), severe
anaemia (haemoglobin< 5 gm/dl), jaundice (detected
clinically or bilirubin> 3 mg/dl), hypoglycaemia (blood
glucose< 40 mg/dl), hyperparasitaemia (parasite count
> 100,000 asexual forms/μl) and severe thrombocytopenia
(<50,000/μL) were managed according to the WHO
guidelines, and the rest were considered as uncomplicated
cases [19].
Thin and Thick blood films were prepared and
stained with 10% Giemsa, and 100 oil immersion
fields were examined. The parasite density was evalu-
ated by counting the number of asexual parasites for
every 200 leukocytes, assuming a leukocyte count of
8000 leukocytes/μl. All slides were double-checked in
a blinded manner and only considered negative if no
parasites were detected in 100 oil immersion fields.
Blood glucose was measured at baseline before quin-
ine infusion, two hours after quinine infusion and if
there was clinical suspicion of hypoglycaemia using
the bedside device Accu-Chek™ Multiclix (Roche diag-
nostics, Mannheim Germany). The Accu-Chek™ ma-
chine was calibrated weekly and every time a new
box of test strips was opened. Blood indices were
performed by hematology analyzer.
Resuscitation and supportive management were
given according to the WHO guidelines [19]; i.e.
quinine infusion at 10 mg/kg three times a day over
2–3 hours changed to oral quinine tablets when
the patient could tolerate them, correction of
hypoglycaemia with 10% glucose, termination of con-
vulsions with intravenous diazepam if this persisted
for more than three minutes. Paracetamol was given
every 6 hours until defervescence. Those with severe
anaemia (haemoglobin< 5 g/dl) and respiratory dis-
tress were transfused with blood screened for hepa-
titis and HIV. Vital signs were measured every 15
minutes for the first hour, then every 2 hours until
24 hours, and thereafter every 6 hours until the dis-
charge from the hospital. Baseline investigations
were performed for every patient on admission and
repeated when clinically indicated. These included
levels of haemoglobin, serum urea, serum creatinine,
and serum bilirubin as well as the white blood cell
count. Patients were discharged home on oral quin-
ine tablets (10 mg/kg every eight hours till day 7)
and primaquine tablets for 15 days.Ethics
The study received ethical clearance from the Research
Board of the Faculty of Medicine, University of Khar-
toum, Sudan.
Results
Among 298 children diagnosed with malaria at the paediat-
ric ward, 79 (18.0%) fulfilled one or more of the WHO cri-
teria for severe malaria [19]. Out of these 79 children with
severe malaria, 61 (77.2%) were severe P. falciparum mal-
aria and 18 (22.8%) [10, 55.6% were male] had various
manifestations of severe P. vivax malaria namely: severe an-
aemia (6, 33.3%), jaundice (5, 27.8%), thrombocytopenia (4,
22.2%), hypotension (3, 16.7%), repeated convulsions (3,
16.7%), cerebral malaria (2, 11.1%), epistaxis (2, 11.1%),
renal impairment (1, 5.5%), hypogylcaemia and more than
one manifestation (5, 27.8%). There was no death among
these patients.
Three patients with severe anaemia received blood trans-
fusion. Out of the six patients with severe anaemia; two
patients had jaundice, one patient had hypotension and
thrombocytopenia. Two patients had an enlarged spleen.
All children were febrile. Different symptoms such as
nausea (14, 77.8%), vomiting (9, 50%), aches (8, 44.4%),
sweating (7; 39.0%), headache (7; 39.0%), and diarrhoea (3;
16.7%) were observed among these children. All of these
cases were P. vivax mono-infections.
The admission characteristics of these children are
shown in Table 1. None of the patients developed
hypoglycaemia during quinine treatment. By day 2, co-
matose patients were fully conscious and all patients
were symptom free and a parasitaemic. All patients
started oral quinine and primaquine tablets within two
days.
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The current study documented the severe manifestations
of P. vivax malaria (anaemia, jaundice, hypotension,
thrombocytopenia, repeated convulsions, cerebral mal-
aria, epistaxis, renal impairment and hypogylcaemia) in
an area characterized by P. falciparum malaria [18]. We
have previously observed the same manifestations of se-
verity that were due to P. falciparum malaria in the
same pediatric ward as well as in the different regions of
Sudan [14-17]. Only 3% of malaria cases (99/1539 blood
films from 190 individuals) in the same setting were P.
vivax while 95% were P. falciparum malaria giving the
rate of P. vivax/P. falciparum malaria of 0.03 [18]. Per-
haps there is an increase in the P. vivax malaria due to
influx of Ethiopian and Eritrean populations through the
border following the peace and construction of Asphalt
roads between these countries and Sudan. Recent
reports showed that most of the malaria infections in
Ethiopia were P. vivax infections and even with reported
treatment failure [20-22]. Our data therefore confirmed
the findings of some authors, who also believe that P.
vivax in not a rare disease in Africa and might use recep-
tors other than Duffy to invade erythrocytes [20-24].
The manifestations of severe P. vivax malaria in this
setting are similar to the severe manifestations of P.
vivax malaria that has been reported from India
[10,12,25-28], Brazil [29], Papua New Guinea [8,30] and
Indonesia [31] both in adults and children.
Generally, according to the WHO guidelines, cere-
bral malaria, severe anaemia, severe thrombocytopenia
and pancytopenia, jaundice, splenic rupture, acute
renal failure and acute respiratory distress syndrome
are the expected manifestations of severe P. vivax
malaria [32]. Severe anaemia and acute pulmonary
oedema are not uncommon. The underlying mechan-
isms of severe manifestations are not fully under-
stood. It worth mentioning that there are no specific
manifestations/treatment of severe P. vivax malaria,
but according the WHO guidelines, prompt and ef-
fective treatment and case management should be the
same as for severe and complicated P. falciparum
malaria [32].
In the current study patients were asymptomatic
within two days following the treatment with quinine.
According to the WHO new guidelines intravenous arte-
sunate is superior to quinine in the treatment of severe
malaria [32]. Compared to quinine, intravenous artesu-
nate has a lower risk of hypoglycaemia, significantly
reduces the risk of death from severe malaria, and does
not require rate controlled infusion/cardiac monitoring
[33]. Yet, intravenous artesunate is not registered and
available in Sudan. Primaquine is currently the only drug
available for radical cure of P. vivax and can be safely
used in children 1 to 10 years of age [34].Conclusion
Severe P. vivax malaria is an existing entity in eastern
Sudan. Further studies involving clinical and molecular
research are required to understand emergence of severe
P. vivax malaria.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HM and IA designed the study. GIG and ER carried out the study and
participated in the procedures. All the authors read and approved the final
version.
Author details
1New Halfa Teaching Hospital, New Halfa, Sudan. 2Faculty of Medicine,
Qassim, University, Qassim, Qassim, Kingdom of Saudi Arabia. 3Buraidah
Central Hospital, Buraidah, Kingdom of Saudi Arabia. 4Faculty of Medicine,
University of Khartoum, Sudan, P.O. Box 102, Khartoum, Sudan.
Received: 31 May 2012 Accepted: 20 July 2012
Published: 30 July 2012
References
1. WHO Global Malaria Programme: World Malaria Report Geneva. Geneva:
World Health Organization; 2010.
2. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH,
Kabaria CW, Tatem AJ, Manh BH, Elyazar IR, Baird JK, Snow RW, Hay SI: The
international limits and population at risk of Plasmodium vivax
transmission in 2009. PLoS Negl Trop Dis 2010, 4(8):e774. 3.
3. Baird JK: Resistance to therapies for infection by Plasmodium vivax. Clin
Microbiol Rev 2009, 22:508–534.
4. Sattabongkot J, Tsuboi T, Zollner GE, Sirichaisinthop J, Cui L: Plasmodium
vivax transmission: chances for control? Trends Parasitol 2004, 20:192–198.
5. Galinski MR, Barnwell JW: Plasmodium vivax: who cares? Malaria J 2008,
7(Suppl 1):S9.
6. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo
HA: Key gaps in the knowledge of Plasmodium vivax, a neglected
human malaria parasite. Lancet Infect Dis 2009, 9:555–566.
7. Wurtz N, Mint Lekweiry K, Bogreau H: Vivax malaria in Mauritania includes
infection of a Duffy-negative individual. Malaria J 2011, 10:336.
8. Manning L, Laman M, Law I, Bona C, Aipit S, Teine D, Warrell J, Rosanas-
Urgell A, Lin E, Kiniboro B, Vince J, Hwaiwhanje I, Karunajeewa H, Michon P,
Siba P, Mueller I, Davis TM: Features and prognosis of severe malaria
caused by Plasmodium falciparum, Plasmodium vivax and mixed
Plasmodium species in Papua New Guinean children. PLoS One 2011,
6(12):e29203.
9. Gogia A, Kakar A, Byotra SP: Is benign tertian malaria actually benign?
Trop Doct 2012, 42:92–93.
10. Naha K, Dasari S, Prabhu M: Spectrum of complications associated with
Plasmodium vivax infection in a tertiary hospital in South-Western India.
Asian Pac J Trop Med 2012, 5:79–82.
11. Singh H, Parakh A, Basu S, Rath B: Plasmodium vivax malaria: is it actually
benign? J Infect Public Health 2011, 4:91–95.
12. Tanwar GS, Khatri PC, Sengar GS, Kochar A, Kochar SK, Middha S, Tanwar G,
Khatri N, Pakalapati D, Garg S, Das A, Kochar DK: Clinical profiles of 13
children with Plasmodium vivax cerebral malaria. Ann Trop Paediatr 2011,
31:351–356.
13. Roder H, Vietze G: Plasmodium vivax infection with brain symptoms.
Dtsch Gesundheitsw 1968, 23:1328–1331.
14. Adam I, Idris HM, Mohamed-Ali AA, Aelbasit IA, Elbashir MI: Comparison of
intramuscular artemether and intravenous quinine in the treatment of
Sudanese children with severe falciparum malaria. East Afr Med J 2002,
79:621–625.
15. Ali AA, Elhassan EM, Magzoub MM, Elbashir MI, Adam I: Hypoglycaemia
and severe Plasmodium falciparum malaria among pregnant Sudanese
women in an area characterized by unstable malaria transmission. Parasit
Vectors 2011, 23(4):88.
16. Eltahir HG, Omer AA, Mohamed AA, Adam I: Comparison of artesunate
and quinine in the treatment of Sudanese children with severe
Mahgoub et al. Parasites & Vectors 2012, 5:154 Page 4 of 4
http://www.parasitesandvectors.com/content/5/1/154Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 2010, 104:684–
686.
17. Mirghani HA, Eltahir HG, A-Elgadir TM, Mirghani YA, Elbashir MI, Adam I:
Cytokine profiles in children with severe Plasmodium falciparum malaria
in an area of unstable malaria transmission in central Sudan. J Trop
Pediatr 2011, 57:392–395.
18. Himeidan YE, Elbashir MI, El-Rayah E-A, Adam I: Epidemiology of malaria in
New Halfa, an irrigated area in eastern Sudan. East Mediterr Health J 2005,
11:499–504.
19. WHO: Severe and complicated malaria. Trans R Soc Trop Med Hyg 2000,
94(Suppl 1):1–90.
20. Woyessa A, Deressa W, Ali A, Lindtjorn B: Prevalence of malaria infection in
Butajira area, south-central Ethiopia. Malaria J 2012, 11:84.
21. Alemu A, Abebe G, Tsegaye W, Golassa L: Climatic variables and malaria
transmission dynamics in Jimma town, South West Ethiopia. Parasites
Vectors 2011, 4:30.
22. Ketema T, Getahun K, Bacha K: Therapeutic efficacy of chloroquine for
treatment of Plasmodium vivax malaria cases in Halaba district, South
Ethiopia. Parasites Vectors 2011, 4:46.
23. Ménard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A,
Thonier V, Carod JF, Domarle O, Colin Y, Bertrand O, Picot J, King CL,
Grimberg BT, Mercereau-Puijalon O, Zimmerman PA: Plasmodium vivax
clinical malaria is commonly observed in Duffy-negative Malagasy
people. Proc Natl Acad Sci USA 2010, 107:5967–5971.
24. Mendes C, Dias F, Figueiredo J, Mora VG, Cano J, De Sousa B, Do Rosário VE,
Benito A, Berzosa P, Arez AP: Duffy Negative Antigen Is No Longer a
Barrier to Plasmodium vivax - Molecular Evidences from the African West
Coast (Angola and Equatorial Guinea). PLoS Negl Trop Dis 2011, 5:e1192.
25. Kaushik JS, Gomber S, Dewan P: Clinical and epidemiological profiles of
severe malaria in children from Delhi, India. J Health Popul Nutr 2012,
30:113–116.
26. Bammigatti C, Shetty S, Shetty S, Kumar A: Benign tertian malaria–a
misnomer? Trop Doct 2011, 41:168–169.
27. Kochar DK, Das A, Kochar SK, Saxena V, Sirohi P, Garg S, Kochar A, Khatri MP,
Gupta V: Severe Plasmodium vivax malaria: a report on serial cases from
Bikaner in northwestern India. AmJTrop Med Hyg 2009, 80:194–198.
28. Yadav D, Chandra J, Aneja S, Kumar V, Kumar P, Dutta AK: Changing profile
of severe malaria in north Indian children. Indian J Pediatr 2012, 79:483–
487.
29. Lança EF, Magalhães BM, Vitor-Silva S, Siqueira AM, Benzecry SG, Alexandre
MA, O'Brien C, Bassat Q, Lacerda MV: Risk factors and characterization of
Plasmodium vivax-associated admissions to pediatric intensive care units
in the Brazilian Amazon. PLoS One 2012, 7(4):e35406.
30. Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, Müller I:
Plasmodium vivax and mixed infections are associated with severe
malaria in children: a prospective cohort study from Papua New Guinea.
PLoS Med 2008, 5(6):e127.
31. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M,
Lampah DA, Price RN: Multidrug-resistant Plasmodium vivax associated
with severe and fatal malaria: a prospective study in Papua. Indonesia
PLoS Med 2008, 5(6):e128.
32. WHO | Guidelines for the treatment of malaria, second edition Publication
date: Languages; 2010. English ISBN: 9789241547925 www.who.int/malaria/
publications/atoz/9789241547925.
33. Sinclair D, Donegan S, Lalloo DG: Artesunate versus quinine for treating
severe malaria. Cochrane Database Syst Rev 2011, 3:CD005967.
34. Betuela I, Bassat Q, Kiniboro B, Robinson LJ, Rosanas-Urgell A, Stanisic D,
Siba PM, Alonso PL, Mueller I: Tolerability and safety of primaquine in
Papua New Guinean children 1 to 10 years of age. Antimicrob Agents
Chemother 2012, 56:2146–2149.
doi:10.1186/1756-3305-5-154
Cite this article as: Mahgoub et al.: Severe Plasmodium vivax malaria
among sudanese children at New Halfa Hospital,
Eastern Sudan. Parasites & Vectors 2012 5:154.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
